A METHOD OF INDUCING MALOLACTIC FERMENTATION IN WINE OR FRUIT JUICE BY DIRECT INOCULATION WITH A NON-ACTIVATED STARTER CULTURE

Abstract: A method of inducing malolactic fermentation in wine or fruit juice by the direct inoculation of a concentrate of a starter culture containing a selected malolactically active bacterial strain having a survival rate of at least 80 % when introduced into a wine having a pH of 3.2 or lower and containing at least 25mg SO2 per L and at least 12 vol % ethanol, and capable of starting malolactic fermentation when added directly to the wine or fruit juice at a concentation of less than 10<7> colony forming units per mL.

Description: A METHOD OF INDUCING MALOLACTIC FERMENTATION IN WINE OR FRUIT JUICE BY DIRECT INOCULATION WITH A NON-ACTIVATED STARTER CULTURE. FIELD OF INVENTION The present invention provides a novel method of inducing the decarboxylation of malic acid to lactic acid in wine or fruit juice by direct inoculation with a non-activated starter culture of malolactically active lactic acid bacteria and a composition comprising bacteria useful in the method. BACKGROUND OF THE INVENTION Grape juice, must and other fruit juice contain a varying amount of L-malic acid and L-malate, the amount typically being in the range of 1 to 10 g/L. The amount of malic acid and malate depends largely on the climatic conditions pre- vailing in the viticultural region. Hence, wines produced in colder areas tend to have a relatively higher acid content, since the malic acid is not degraded during the normal al¬ coholic fermentation. From a taste and flavour point of view, malic acid is considered undesirable in most red wines and in several types of rose wines, white wines or sparkling wines. However, the content of malic acid and malate in a wine may be reduced by a so-called malolactic fermentation (MLF) of the wine which fermentation results from the metabolic ac¬ tivity of various lactic acid bacteria, including species belonging to the genera of Lactobacillus. Pediococcus and Leuconostoc. Such bacteria may be present in must and wine as part of the indigenous microbial flora hereof, or they may have been added as a bacterial starter culture. Typically, the MLF is associated with malolactic bacterial growth and catabolic processes during which the wine acidity is reduced. The catabolic phase is usually entered when the malolacti¬ cally active bacteria during the growth phase has reached a population density of about 10 6 colony forming units (CFU) per L. The microbial malolactic deacidification results from the decarboxylation of the dicarboxylic acid, L-malic acid to the monocarboxylic acid, L-lactic acid. As a result of this malolactic fermentation, the acidity of the wine decreases and the pH increases, resulting in a wine with a softer palate relative to that of the wine before the malolactic fermentation. Following a successful malolactic fermentation in wine, no further microbial growth will normally occur and hence, the wine is considered to be microbiologically stable. The malolactic fermentation may occur spontaneously in the wine as a result of the growth of an indigenous flora of malolactically active lactic acid bacteria originating from the vines and grape skins and also often surviving from one season to the next on winery equipment, especially wooden casks or other equipment made of wood. When occurring in this fashion, malolactic fermentation is often delayed and may take place several months after the alcoholic fermentation. The initial number of bacteria is often quite small and the environment of the wine is frequently rather hostile to the growth of these bacteria due to the content of ethanol and sulphur dioxide in the wine, as well as its low pH and low nutrient concentration. The extended lag phase of the malo¬ lactic bacteria during which the wine is biologically un¬ stable may result in the growth of bacteria producing vola- tile acidity and hence spoilage of the wine. Apart from this, certain indigenous malolactic bacteria spontaneously growing in the wine may produce certain compounds, e.g. biogenic amines that are believed to give rise to health problems. In the traditional winery industry where the spontaneously occurring malolactic fermentation is being relied upon, it is common practice to stimulate malolactic fermentation by reducing the amount of added sulphur when determined as sulphur dioxide, to below 50 mg per L, delaying the removal of the lees, increasing the temperature of the wine to above 20°C, or ensuring a pH of more than 3.4. These measures, however, may also favour the growth of undesired microor¬ ganisms in the wine such as Acetobacter species, thus in¬ creasing the likelihood of wine spoilage, and this approach therefore requires extremely careful supervision of the decarboxylation process. Even if precautions are taken to enhance spontaneous MLF, this process is still difficult, not to say impossible, to control, and its occurrence has become even more unpredictable as winery hygiene has improved e.g. as a result of the replacement of wooden casks with stainless steel tanks. Such hygienic measures serve to ensure a uniform quality of the wine and reduce the risk of spoilage. However, they also reduce the chance of spontaneous conversion of malic acid taking place in the wine. For this reason, and because the winemaker will often prefer to exercise a greater degree of control over the malolactic fermentation process it has become increasingly common prac¬ tice in the winery industry to add a starter culture of malolactically active bacteria to the wine after the alcoho¬ lic fermentation. Presently, such a postfermentation malolac- tic fermentation in wine may be induced in different ways. Currently, a widely practiced method of inducing MLF is to seed a wine with a small proportion of another wine already undergoing MLF and thus containing a high number of viable malolactically active bacteria. The culture in the seed wine is then already well adapted to wine conditions and will usually be capable of completing the malolactic fermentation in the seeded wine. However, this method of inoculation is rather tedious and not completely controllable. Thus, the method requires that a concentrated "mother culture" of the bacteria is propagated for an extended period of time, such as about two months, in diluted wine or grape juice, optio¬ nally after rehydration and/or adaptation of the mother culture in e.g. a grape fruit juice-containing medium which is then used to inoculate the wine to be used as a bulk starter culture in the form of seed wine. Typically, the wine is inoculated with the seed wine at a rate of 1 to 10 vol%. and accordingly, this method requires substantial investments in propagation equipment and adequately trained staff. In addition, it is difficult to control the propagation process and hence serious timing problems may occur. Should both red " and white wine starter cultures be required these problems are doubled. Relative to the above practice of using a seed wine, a post- fermentation inoculation of wine with concentrated freeze- dried or frozen starter cultures of malolactically active lactic acid bacteria implies considerable savings in time and labour by substantially reducing the amount of scale-up work required. Such concentrated starter cultures are now commer¬ cially available and their use is being increasingly accepted in the wine industry, although their malolactic effect is not completely reliable. These culture compositions may be con¬ centrated to contain a number of colony forming units which, when determined in a non-inhibitory medium is in the range of 10 9 to 10 11 per g of culture. However, the use of known, commercially available malolac- tically active culture compositions contain bacteria which are susceptible to the conditions (low pH, content of S0 2 , content of ethanol) prevailing in the fermented wine and accordingly, their malolactic efficiency requires that they become adapted to the hostile conditions in the wine by a carrying out a thawing and rehydration step (if freeze- dried) , a thawing step (if frozen) and an activation step prior to inoculation in the wine. This requirement is assu- ingly due to the well-known phenomenon that a freeze-dried or frozen lactic acid bacterial culture composition, even if it includes additives protecting the bacteria against cell damages, will as a result of the freezing and/or freeze- drying process have an increased susceptibility to low pH, S0 , ethanol and low temperatures as compared to a freshly grown culture of the same species. If not rehydrated and activated as described above, the survival rate of the known commercial malolactic compositions on direct inoculation into wine will typically be in the range of 0.01 to 1% or even lower. Furthermore, the initially" surviving non-adapted bacteria may gradually loose their viability in the wine. Typically, this required adaptation comprises an initial thawing and/or rehydration process, the latter comprising dissolving the freeze-dried composition in water and adding various nutrients such as a sugar, vitamins, minerals or yeast extract and keeping the resulting solution at about 22°C for about one hour. Subsequently, the thus rehydrated composition is subjected to an activation step, typically lasting 48 to 84 hours, in a medium which typically comprises grape juice or wine diluted with water, yeast extract, trace elements and vitamins. Normally, the number of CFUs does not increase during this activation period, on the contrary, the number may decrease. Even if the starter culture composition is adapted as described above, a varying proportion of adap- ted bacteria may loose viability as determined in a non- inhibitory medium when inoculated in wine. This loss of viability may be up till 90% of the added number of CFUs. In EP-A1-0141878 is disclosed a method of reducing malic acid to lactic acid in wine by the introduction of high numbers of bacterial cells into the wine, which method comprises ac¬ tivating a concentrate of a bacterial culture in a nitrogen source-augmented fruit juice to form an activated mixture of bacteria containing at least about 10 5 CFUs per mL and intro¬ ducing the activated mixture into wine or grape must and converting the malic acid to lactic acid. The activation conditions disclosed are an activation period of 48 hours at 24°C. Krieger et al. (Food Biotechnol. 1990, 7., 484) have disclosed the application in wine of malolactically active strains of Leuconostoc oenos and Lactobacillus spp. in the form of fresh or frozen concentrates using direct inoculation, i.e. without preceding activation, of at least 10 7 CFUs per mL which concentration is indicated as being necessary to start malo¬ lactic fermentation. However, the application of such a high - concentration of malolactictically active organisms is not commercially feasible in the wine industry due to the high cost of starter cultures. The necessity to apply at least 10 7 CFUs per mL as disclosed in order to start MLF may indicate that the survival rate of these organisms when applied directly to the wine is so low that a malolactically active concentration of the organisms is only achieved at the in¬ dicated inoculation level. The present invention provides, compared to the known me¬ thods, a significantly improved method of inducing malolactic fermentation in wine or fruit juice whereby it has become possible to achieve an effective malolactic fermentation herein wihtin a short period of time by inoculating wine or a fruit juice directly with a concentrated culture composition of malolactically active bacteria at an economically feasible concentration and accordingly, to avoid the tedious and costly processes of rehydration, activation, adaptation and/or expansion which are currently required with commercial malolactically active starter cultures. SUMMARY OF THE INVENTION Accordingly, the present invention relates in a first aspect to a method of inducing in a wine or a fruit juice the con¬ version of malic acid to lactic acid comprising the steps of selecting a strain of malolactically active bacteria, capable of starting malolactic fermentation in a wine or fruit juice when added directly thereto at a concentration of less than 10 7 CFUs per mL, providing a concentrate of the selected malolactically active bacterium, introducing said concentrate directly into the wine or the fruit juice, and converting the malic acid while keeping the wine or the fruit juice under conditions which allow conversion of the malic acid to obtain a malolactically fermented wine or fruit juice having a content of malic acid which is at the most 0.5 g per L. In a further aspect, the invention provides a selected strain of a malolactically active bacterium which, when it is added to a wine or fruit juice in a frozen or freeze-dried state at a concentration of CFUs which is in the range of 1 x 10 6 to 5 x 10 7 per mL of the wine or fruit juice, is capable of redu¬ cing at least 4 g of malic acid per L of wine or fruit juice to less then 0.5 g per L within a period of time which is at the most 15 days, said strain having at least one of follow¬ ing characteristics: (a) capable of decarboxylating malic acid in wine at a pH of 3.2 or lower, (b) capable of decarboxylating malic acid in wine in the presence of 25 mg S0 2 per L or more, and (c) capable of decarboxylating malic acid in wine having an ethanol content of 10 vol% or higher. (d) a survival rate of at least 80% when introduced directly into a wine having a pH of 3.2 or lower and containing at least 10 vol% ethanol, (e) a survival rate of at least 50% when introduced directly into a wine having a pH of 3.2 or lower and containing at least 25 mg S0 2 per L and at least 12 vol% ethanol, (f) resistant to . .tack by bacteriophages, (g) capable of retaining at least one of the charac¬ teristics (a) through (f) during propagation and concentration. In a still further aspect, the invention relates to a con¬ centrate of one or more of the selected strains of malolac¬ tically active bacteria as defined herein, and in another aspect there is provided a malolactic starter culture compo- sition comprising a concentrate of selected malolactically active bacterial strain(s) , as defined herein and at least one further ingredient selected from cryoprotectants, bac¬ terial nutrients and bulking agents. DETAILED DISCLOSURE OF THE INVENTION The present invention relates in one aspect to a novel method of inducing the decarboxylation of malic acid to lactic acid in wines and fruit juices by direct inoculation of the wine or fruit juice with appropriately selected malolactically active bacteria. In the present context, the term "wine" is used to describe a product resulting from an alcoholic fermentation of juice or must of grapes or of any other fruit or berries, whether the fermentation occurs spontaneously or it is obtained by the addition of a yeast culture. A wine made from grapes may be a red wine, a white wine, a rose wine, all of which may be in the form of sparkling wines. The conditions prevailing in wine at the completion of the alcoholic fermentation is generally unfavorable for microbial growth. These adverse conditions include a pH typically being in the range of 2.8 to 4.0 such a pH of 3.2 or lower, an ethanol content which is typically in the range of 8 to 14 vol%, such as in the range of 10 to 12 vol%, a low content of nutrients such as carbon sources due to the depletion of the nutrients during the alcoholic fermentation. In addition, a sulphur-containing substance may have been added as a preser¬ vative to the must in an amount which is typically in the range of 5 to 70 mg per L including amounts of 25 mg of S0 2 as defined below per L in the fermented wine, or higher. In this connection it should be noted that the addition of sulphur-containing substances to must is conventionally carried out by the addition of a sulphite or another water soluble sulphur-containing substance. In the fermenting must the sulphite is at least partially converted to S0 2 , the extent of the conversion depending i.a. on the pH. Part of the generated S0 2 will be in the form of free molecules and part will be bound. In the art, the content of sulphur in must or wine is determined by measuring the total content of sulphur-containing substances as total S0 2 . Accordingly, when used herein the term "S0 2 " denotes the total content of sulphur determined according to the Rebelein method in which all sulphur-containing.substances are converted to S0 2 before the measuring step. These conditions in the wine, singly and in combination provides a rather hostile environment for bacteria, including malolactically active lactic acid bacteria. Such bacteria are primarily organisms belonging to the genera of Leuconostoc. Lactobacillus and Pediococcus. Among these genera of natural¬ ly occurring malolactically active bacteria, organisms be¬ longing to Leuconostoc are generally most tolerant to low pH and they may grow at pH values below 3.3. At more moderate pH values such as pH of 3.6 and above, species of Lactobaci1lus and Pediococcus may grow as well. Within the Leuconostoc genus, the species Leuconostoc oenos is particularly adapted to grow in wines and this species is commonly used in commer¬ cial cultures as described above. Species of Lactobacillus which are of particular interest as malolactic starter cul¬ ture organisms include Lactobacillus casei. Lactobacillus brevis. Lactobacillus hilqardii and Lactobacillus plantarum. However, within a species of malolactically active bacteria there may exist differences between different isolates as to tolerance to one or more of the above-mentioned adverse conditions in wine. Accordingly, it may by applying appro¬ priate methods be possible to select, within a species of malolactically active bacteria, isolates (strains) which are - particularly tolerant to one or more of the adverse condi¬ tions. However, it is known in the art that when selecting a bacterial strain against one desired characteristic, such a strain will frequently be industrially less useful due to deficiencies as to other desired characteristics. E.g. may a strain selected on the basis of a high tolerance to acidic conditions be susceptible to moderate amounts of ethanol. In a first step of the presently claimed method, a selection is carried out to obtain a strain of malolactically active bacteria, capable of starting malolactic fermentation in wine or fruit juice when added directly thereto at a concentration of less than 10 7 CFUs per mL, the strain having at least one of the following characteristics: (a) capable of decarboxylating malic acid in wine at a pH of 3.2 or lower, (b) capable of decarboxylating malic acid in wine in the presence of 25 mg S0 2 per L or more, (c) capable of decarboxylating malic acid in wine having an ethanol content of 10 vol% or higher, (d) a survival rate of at least 80% when introduced into a wine having a pH of 3.2 or lower and containing at least 10 vol% ethanol, (e) a survival rate of at least 50% when introduced into a wine having a pH of 3.2 or lower and containing at least 25 mg S0 2 per L and at least 12 vol% ethanol, (f) resistant to attack by bacteriophages, or (g) capable of retaining at least one of the characteris¬ tics (a) through (f) during propagation and concentra¬ tion. When the selection criteria as those defined above have been determined, appropriate selection procedures known per se in the art can readily be chosen. Initially, a large number of strains of malolactically active bacteria are isolated from different types of wines and preferably from a range of viticultural regions. Such isolates may subsequently be tested individually according to each of the above selection criteria, or a number of the isolates may more conveniently be combined and subjected to a first selection in a wine used as a growth medium in a turbidostat fermentor to obtain selection of strains which are capable of growing in a wine at a low pH and a high ethanol content. When using such a turbidostat growth selection procedure, the mixture of isolates are inoculated into a fermentor and the biomass is kept constant by means of a turbidometer. The culture is fed a nutrient-enriched wine with an increasing concentration of ethanol and a decreasing pH. When the pH level and the ethanol concentration is so high that no fur¬ ther bacterial growth is possible, a sample of the culture is drawn :2id representative strains of viable malolactically active bacteria are isolated and characterized. In a second selection step, the isolated, acid and ethanol tolerant strains are tested in wines having different compo¬ sitions for the characteristics (a) through (f) as mentioned above. In a next step, chosen strains are subjected to fer¬ mentor propagation under normal production conditions in order to select strains which have an industrially feasible growth yield and which at the same time maintain the charac¬ teristics based on which they were selected. In a final selection step, the strains which pass the prece¬ ding step is subjected to a down-stream process including at least one of the following steps: harvesting of cells from the culture medium, concentration of the cells, freezing of the concentrate or freeze-drying. It will be understood that a selected strain should prefer- ably have as many as possible of the above-defined charac¬ teristics (a) through (g) . Accordingly, the selected strain is preferably one which has at least two of the characte¬ ristics, more preferably one having at least three of the characteristics and most preferably the strain is one which has all of the defined characteristics. In particular, the selected strain should in addition to other advantageous characteristics have a high rate of survival under the condi¬ tions as defined aboved. A high survival rate makes it pos¬ sible to have the MLF started at the low CFU concentrations as defined above and allow the high proportion of surviving cells to enter the active growth phase and becoming malolac¬ tically active essentially momentaneously or within a short period of time such as within 1-3 days, thereby obtaining the malolactically fermented wine or fruit juice within the short periods of time as defined herein. It may be observed with cultures having a low survival rate and applied in high concentrations that although an initial conversion of malic acid takes place due to the release of malolactically active enzymes from the killed cells, the active growth phase is entered only after a prolonged lag phase of 5-10 days and accordingly, such cultures will not be suitable for obtaining a rapid MLF and particularly, these cultures will not result in a conversion of high amounts of malic acid wihtin an industrially acceptable period of time, such as it is ob- tained with the present selected strains. In accordance with the invention, a suitable malolactically active bacterial strain is one selected from a species be¬ longing to the genera of Leuconostoc. Lactobacillus and Pediococcus. When the strain is selected from a species of the Leuconostoc genus, the species is preferably Leuconostoc oenos such as a strain which is selected from the group consisting of DSM 7008, DSM 7009, DSM 7010, DSM 7011, DSM 7012, DSM 7013, DSM 7014 and DSM 7015. These 8 strains were deposited on 26 March, 1992 with Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German Collection of Microorganisms and Cell Cultures) , Braunschweig, Germany. In a second step of the method as claimed herein, there is provided a concentrate of the thus selected malolactically active strain. The concentrate is preferably one in which the number of colony forming units is in the range of 10 9 to 10 12 per g. In more preferred embodiments, the concentrate has a number of colony forming units which is in the range of 10 11 to 10 12 per g. As an initial step in the obtainment of the concentrate, a chosen selected strain is propagated according to processes which are well-known in the art. Such processes include the step of cultivating the strain in a suitable fermentor vessel containing a suitable growth medium containing sufficient amounts of nutrients required for economically feasible growth yield of the particular strain. In accordance with the invention, a suitable growth medium for propagation of malo¬ lactically active bacteria contains as the major ingredient grape juice to which may be added yeast concentrate or ex¬ tract, malic acid, a surface active substance such as Tween™ 80, a manganese salt, water and a vitamin mixture. In prefer- red embodiments of the invention, the pH in the growth medium is in the range of 4 to 6. Subsequent to the above propagation step, the cell biomass is harvested e.g. by centrifugation whereby a concentrate of cells is obtained in the form of a slurry or a cell paste. Alternatively, the concentrate of cells may be obtained by a filtration process. Although such a fresh cell paste may be used to inoculate a wine or fruit juice, the bacterial con¬ centrate is more conveniently provided in the form of a preserved concentrate, since the viability of cells in a cell paste concentrate will decrease rapidly and furthermore, a fresh cell paste will be prone to growth of contaminating microorganisms. In accordance with the invention, a concen¬ trate may be preserved by freezing e.g. by dripping the paste into liquid nitrogen or by introducing the cell paste into a * suitable freezing apparatus. In order to retain the viability of cells during freezing, the paste may be mixed with suit¬ able cryoprotectants such as gelatine, prior to freezing. In a preferred embodiment of the invention, the concentrate is provided as a freeze-dried concentrate which is typically prepared by subjecting a frozen concentrate to a conventional freeze-drying process. In a subsequent step of the claimed method, a concentrate of the selected malolactically active strain is inoculated directly into the malic acid-containing wine or fruit juice. In the present context, the term "inoculated directly" is used to describe that the concentrate as defined herein is added to the wine or fruit juice without any prior rehydra- tion and/or activation step. As it has been explained above, the known commercial malolactic starter cultures for post- alcoholic MLF all require that they are subjected to an adaptation step including an activation step and optionally (if they are in a freeze-dried state) an initial rehydration step, prior to inoculation. If such known cultures are inocu¬ lated directly, the viability of the cells is typically reduced by a factor of 100 to 1000. The concentrate is added to the wine or the fruit juice in an amount which results in the introduction of a number of bacteria, calcutated on a CFU basis which is in the range of 10 5 to 10 7 per mL. The preferred inoculation rate depends on several factors including the amount of malic acid to be converted, the desired period for obtaining the malolactical¬ ly fermented wine or fruit juice and the temperature condi¬ tions. A typical preferred inoculation rate will be in the range of 10 6 to 10 7 CFUs per mL and a more preferred range may be 5 x 10 6 to 1 x 10 7 CFUs per mL. In the final step of the method as claimed herein, the malic acid is converted to lactic acid while keeping the inoculated wine or fruit juice under conditions which will allow the conversion to take place. In particular, it is required to keep the wine or the fruit juice at a temperature where the inoculated culture is malolactically active. The majority of malolactic bacteria will be active at temperatures in the range of about 12 to about 25°C. A typical temperature for storing wine undergoing malolactic fermentation will be in the range of about 15 to 22°C. As mentioned above, the content of malic acid in a wine may vary, in particular according to the climatic conditions of the viticultural region. Typically, the malic acid content will be in the range of 2 to 10 g per L. In specific embo- diments of the invention, the wine or fruit juice to be malolactically fermented as defined herein is one having a malic acid content of at least 4 g per L, such as at least 5.5 g per L. In accordance with the invention, a malolacti¬ cally fermented wine or fruit juice containing less than 0.5 g malic acid per L should preferably be obtained from such a wine or fruit juice within a period of time which is at the most 15 days. In more preferred embodiments, the period of time is at the most 12 days and in still more preferred embodiments it is at the most 10 days such as at the most 8 days. In particularly preferred embodiments of the present inven¬ tion, the obtained malolactically fermented wine or fruit juice has a malic acid content which is at the most 0.1 g per L. As mentioned above, the present invention relates in further aspects to a strain of a malolactically active bacterium which has been selected according to the methods and selec¬ tion criteria as defined above and to a concentrate of such a selected strain as also defined above. Finally, the present invention provides a malolactic starter culture composition comprising the concentrate as defined herein and at least one further ingredient selected from cryoprotectants, including as an example gelatine, bacterial - nutrients and bulking agents. Conveniently, the claimed composition is preserved to obtain a commercial product which has a suitable shelf-life when stored and distributed appropriately. Accordingly, the compo¬ sition is suitably a frozen or a freeze-dried composition which has been prepared by subjecting a mixture of the bac¬ terial concentrate and the further ingredient(s) to a free¬ zing and/or freeze-drying process essentially in accordance with the above-mentioned processes used for the claimed concentrate. Preferably, the composition is one having a content of colony forming units which is in the range of 10 9 to 10 12 per g, such as in the range of 10 11 to 10 12 per g. In useful embodiments of the invention, the composition is one which when it is inoculated directly into a wine or a fruit juice containing at least 4 g of malic acid per L such as at least 5.5 g per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 15 days, preferably at the most 12 days and more preferably at the most 10 days such as at the most 8 days. It may be advantageous to provide the claimed composition as a composition comprising a multiplicity of the hereindefined selected strains of malolactically active bacteria. Accor- dingly, in one embodiment the composition comprises such a multiplicity. DESCRIPTION OF DRAWINGS The invention is further explained below with reference to the drawings in which Fig. 1 shows the survival and growth (%CFU/mL) of Leuconostoc oenos strain DSM 7008 as fresh culture (fermentate) and as processed concentrates after direct inoculation into wine made from Riesling grape juice (11.5 vol% ethanol, 0 mg S0 2 per L, pH 3.15) of 3 x 10 6 to 7 x 10 6 per mL. Fig. 2A shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Chenin white wine (10.5 vol% ethanol, 16 mg S0 2 /mL, pH 3.5, 0.004 g/L of glucose and 0.003 g/L of fructose) kept at 18°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7008, and in the same wine without inocula- tion. Fig. 2B shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.0 vol% ethanol, 0 mg S0 2 /mL, pH 3.6, 0.11 g/L of glucose and 0.07 g/L of fructose) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7008, and in the same wine without inoculation. Fig. 2C shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.3 vol% ethanol, 0 mg S0 2 /mL, pH 3.6, 0.11 g/L of glucose and 0.07 g/L of fructose) kept at 21°C in 10.000 L insulated tanks inoculated with a freeze-dried composition of Leuco¬ nostoc oenos strain DSM 7008, and in the same wine without inoculation. Fig. 2D shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.8 vol% ethanol, 5 mg S0 2 /mL, pH 3.5, 0.3 g/L of glucose and 0.45 g/L of fructose) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7008, and in the same wine without inoculation. Fig. 2E shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.8 vol% ethanol, 5 mg S0 2 /mL, pH 3.5, 0.3 g/L of glucose and 0.45 g/L of fructose) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7008, and in the same wine without inoculation. Fig. 2F shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.0 vol% ethanol, 0 mg S0 2 /mL, pH 3.6, 0.11 g/L of glucose and 0.07 g/L of fructose) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7015, and in the same wine without inoculation. Fig. 2G shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Sauvignon red wine (11.8 vol% ethanol, 5 mg S0 2 /mL, pH 3.5, 0.3 g/L of glucose and 0.45 g/L of fructose) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain DSM 7015, and in the same wine without inoculation. Fig. 2H shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Cabernet Franc red wine (13.0 vol% ethanol, 2 mg S0 2 /mL, pH 3.4) kept at 20°C in 5 L jars inoculated with a freeze-dried composition of Leuco- nostoc oenos strain DSM 7008, and in the same wine without inoculation. Fig. 21 shows the conversion of malic acid and CFU/mL of malolactically active bacteria in Semillon white wine (12.2 vol% ethanol, 26 mg S0 2 /mL, pH 3.2) kept at 19°C in 5 L jars inoculated with a freeze-dried composition of Leuconostoc oenos strain, DSM 7008, and in the same wine without inocula¬ tion. EXAMPLE 1 Survival and growth of Leuconostoc oenos in an experimental wine An experimental wine was prepared by yeasting a sterile Riesling grape juice originating from Germany, without the addition of sulphite. After completion of the alcoholic fermentation, the wine was sterile filtered and the resulting wine had the following composition: Ethanol 11.5 vol% Malic acid 3.9 g/L Residual sugar 3.5 g/L pH 3.15 A culture of Leuconostoc oenos strain DSM 7008 was prepared, and the sterile wine was inoculated with (1) cells of the strain directly from the fermentate (i.e. the growth medium containing an outgrown culture of the strain) , (2) a cell concentrate after centrif gation, (3) a cell concentrate to which cryoprotective agents had been added or (4) a freeze- dried composition of a cell concentrate with added cryopro- tectants, respectively. The numbers of CFUs which were inocu¬ lated by the four mentioned forms of the strain varied between 3 x 10 6 and 7 x 10 6 per mL of the experimental wine. The survival of the added bacteria in the wine kept at 20°C was monitored over 3 days, samples being collected on day 2 and 3 and the number of CFUs herein being determined accor¬ ding to standard methods for determining viable counts of Leuconostoc oenos. The results of this experiment are shown in Fig. 1 from which it appears that the bacteria when added in the form of a fermentate multiplied during the keeping time, with a factor of about 6. Bacteria added in the form of processed inocula showed a survival rate after 2 days which was in the range of 80% to 100% and during the next day the numbers of CFUs of these inocula increased by 10% to 60% relative to the initial numbers. EXAMPLE 2 Induction of malolactic fermentation in Bordeaux red wines and white wines by direct inoculation with Leuconostoc oenos- containincr compositions The malolactic effect of freeze-dried compositions of two strains of Leuconostoc oenos, DSM 7008 and DSM 7015 were tested by direct inoculation into different wines. The study was carried out by inoculating wines in 5 L jars and in industrial scale by inoculating wines contained in 5.000 to 10.000 L tanks. The inoculum level was about 5 x 10 6 per mL of wine. The study comprised the following experiments: 1. Inoculation with strain DSM 7008 of Chenin white wine from the Loire region contained in 5 L jars. 2. Inoculation with strains DSM 7008 and DSM 7015 of Cabernet Sauvignon red wine from Graves in the Bordeaux region, kept in 5 L jars and additionally with DSM 7008 in a 10.000 L tank. 3. Inoculation with strains DSM 7008 and DSM 7015 of Cabernet Sauvignon red wine from Premieres Cotes de Bordeaux contained in 5 L jars and additionally with strain DSM 7008 in a 5.000 L tank. This wine had a content of ethanol of 11.8 vol% and a S0 2 content of 5 mg per L and a pH of 3.5. 4. Inoculation with strain DSM 7008 of Cabernet-Franc red wine from Premieres Cotes de Bordeaux, kept in 5 L jars. 5. Inoculation with strain DSM 7008 of Semillon white wine from Cotes de Montravel in the Bordeaux region, kept in 5 L jars. The tested wines had an initial content of malic acid in the range of 3 to 5.5 g per L, and the content of S0 2 was in the range of 0 to 26 mg per L. In all of the inoculated wines the malolactic fermentation occurred at a rate which resulted in a substantially complete disappearance of malic acid within 8 to 20 days. The survival rate of the inoculated bacteria was 90 to 100% in the test wines and in most wines an increase of CFUs up till about 10 8 per mL occurred during the malolactic fermentation period. INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 136is) A. The indications made below relate to the microorganism referred to in the description on page 13 , line B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sairanlung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) M scheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7011 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This infoimation is continued on an additional sheet [X] As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belowwill be submitted to the International Bureau \zttr(speάfythegenσalnatureoftheindica onscg., 'Accession Number of Deposit') For International Bureau use only I j This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 13 , line 2 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ft j Name of depositary institution DSM Deutsche Sam lung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7012 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This infoimation is continued on an additional sheet [X] As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (fø v blankifnot applicable) The indications listed belowwill be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit') For International Bureau use only I I This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) The indications made below relate to the microorganism referred to in the description on page 13 , line 2 B. roENTEFTCATTON OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7013 C. ADDITIONAL INDICATIONS (teαvr blank if not applicable) Tin's infoimation is continued on an additional sheet [^ As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belowwill be submitted to the International Bureau later (specify the general nature o th indications e.g., 'Accession Number of Deposit') For International Bureau use only I I This sheet was received by the International Bureau on: Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 1_3 . line 2 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7014 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [^ As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belo ill be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit') For International Bureau use only I I This sheet was received by the International Bureau on: Authorized officer Form PCT7RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 13 , line B. roENTTFICATTON OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) ' Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7015 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [ TJ As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms.only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be ithdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belowwill besubmitted to the International Bureau later (specify the general nature of the indications eg., 'Accession Number of Deposit') For International Bureau use only I I This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134(JuIy 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) A. The indications made below relate to the microorganism referred to in the description on page 13 , line 1 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Name of depositary institution DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7008 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ^ As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms.only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit') For International Bureau use only I j This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 13 . line 1 B. IDENΠFICATION OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sammlunσ von Mikroorganismen und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7009 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This infoimation is continued on an additional sheet ^] As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listedbelowwiil besubmitted to the International Bureau later (speafythegeneralnatureoftheindicationse.gr, 'Accession Number of Deposit') INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) A. The indications made below relate to the microorganism referred to in the description on page 13 . line 1 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ft | Name of depositary institution DSM Deutsche Sammlung von Mikroorganis en und Zellkulturen GmbH Address of depositary institution (including postal code and country) Mascheroder Weg 1 B D-3300 Braunschweig Date of deposit Accession Number 26 March 1992 DSM 7010 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [^ As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been re¬ fused or withdrawn or is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belowwill be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit') For International Bureau use only I j This sheet was received by the International Bureau on: Authorized officer Foπn PCT/RO/134 (July 1992)

Claims: CLAIMS 1. A method of inducing in a wine or a fruit juice the con¬ version of malic acid to lactic acid comprising the steps of - selecting a strain of malolactically active bacteria, capable of starting malolactic fermentation in a wine or fruit juice when added directly thereto at a concentration of less than 10 7 CFUs per mL, providing a concentrate of the selected malolactically active bacterium, introducing said concentrate directly into the wine or the fruit juice, and converting the malic acid while keeping the wine or the fruit juice under conditions which allow conversion of the malic acid, to obtain a malolactically fermented wine or fruit juice having a content of malic acid which is at the most 0.5 g per L. 2. A method according to claim 1 wherein the wine or the fruit juice has a pH which is at the most 3.2. 3. A method according to claim 1 wherein the wine is a red wine. 4. A method according to claim 1 wherein the wine is a wine selected from a white wine and a sparkling wine. 5. A method according to claim 1 wherein the malolactically active bacterial strain is one selected from the group con¬ sisting of a Leuconostoc species, a Lactobacillus species and a Pediococcus species. 6. A method according to claim 5 wherein the selected bac- terial strain is a strain of Leuconostoc oenos. 7. A method according to claim 6 wherein the strain of Leuco¬ nostoc oenos is a strain selected from the group consisting of DSM 7008, DSM 7009, DSM 7010, DSM 7011, DSM 7012, DSM 7013, DSM 7014 and DSM 7015. 8. A method according to claim l wherein the selected bac¬ terial strain has at least one of following characteristics: (a) capable of decarboxylating malic acid in wine at a pH of 3.2 or lower, (b) capable of decarboxylating malic acid in wine in the presence of 25 mg S0 2 per L or more, (c) capable of decarboxylating malic acid in wine having an ethanol content of 10 vol% or higher, (d) a survival rate of at least 80% when introduced into a wine having a pH of 3.2 or lower and contain¬ ing at least 10 vol% ethanol, (e) a survival rate of at least 50% when introduced into a wine having a pH of 3.2 or lower and contain¬ ing at least 25 mg S0 2 per L and at least 12 vol% ethanol, (f) resistant to attack by bacteriophages, or (g) capable of retaining at least one of the charac¬ teristics (a) through (f) during propagation and concentration. 9. A method according to claim 8 wherein the selected bac¬ terial strain has at least two of the characteristics (a) through (g) . 10. A method according to claim 9 wherein the selected bac¬ terial strain has at least three of the characteristics (a) through (g) . 11. A method according to claim 10 wherein the selected bacterial strain has all of the characteristics (a) through ( g ) . 12. A method according to claim 1 wherein the provided con- centrate has a content of colony forming units which is in the range of 10 9 to 10 12 per g. 13. A method according to claim 12 wherein the concentrate has a content of colony forming units which is in the range of 10 11 to 10 12 per g. 14. A method according to claim 1 wherein the concentrate is preserved. 15 A method according to claim 14 wherein the preserved concentrate is frozen. 16. A method according to claim 14 wherein the preserved concentrate is freeze-dried. 17. A method according to claim 1 wherein the concentrate is added in an amount resulting in the introduction into the wine or fruit juice of a number of the malolactically active bacteria which is in the range of 10 5 to 10 7 CFU per mL. 18. A method according to claim 17 wherein the number of the malolactically active bacteria being introduced into the wine or the fruit juice is in the range of 10 6 to 10 7 . 19. A method according to claim 18 wherein the number of the malolactically active bacteria being introduced into the wine or the fruit juice is in the range of 5 x 10 6 to 10 7 . 20. A method according to claim 1 wherein the wine or fruit juice has a content of malic acid which is at least 4 g per L. 21. A method according to claim 20 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 15 days. 22. A method according to claim 21 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 10 days. 23. A method according to claim 22 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 8 days. 24. A method according to claim 1 wherein the wine or fruit juice has a content of malic acid which is at least 5.5 g per L. 25. A method according to claim 24 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 15 days. 26. A method according to claim 25 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 10 days. 27. A method according to claim 26 wherein the period of time to obtain the resulting malolactically fermented wine or fruit juice is at the most 8 days. 28. A method according to claim 1 wherein the obtained malo¬ lactically fermented wine or fruit juice has a content of malic acid which is at the most 0.1 g per L. 29. A selected strain of a malolactically active bacterium which, when it is added to a wine or fruit juice in a frozen or freeze-dried state at a concentration of CFUs which is in the range of 1 x 10 6 to 5 x 10 7 per mL of the wine or fruit juice, is capable of reducing at least 4 g of malic acid per L of wine or fruit juice to less then 0.5 g per L within a period of time which is at the most 15 days, said strain having at least one of which is a strain having at least one of following characteristics: (a) capable of decarboxylating malic acid in wine at a pH of 3.2 or lower, (b) capable of decarboxylating malic acid in wine in the presence of 25 mg S0 2 per L or more, (c) capable of decarboxylating malic acid in wine having an ethanol content of 10 vol% or higher, (d) a survival rate of at least 80% when introduced into a wine having a pH of 3.2 or lower and contain¬ ing at least 10 vol% ethanol, (e) a survival rate of at least 50% when introduced into a wine having a pH of 3.2 or lower and contain- ing at least 25 mg S0 2 per L and at least 12 vol% ethanol, (f) resistant to attack by bacteriophages, or (g) capable of retaining at least one of the charac¬ teristics (a) through (f) during propagation and concentration. 30. A strain according to claim 29 which is a strain having at least two of the characteristics (a) through (g) . 31. A strain according to claim 30 which is a strain having at least three of the characteristics (a) through (g) . 32. A strain according to claim 31 which is a strain having all of the characteristics (a) through (g) . 33. A strain according to claim 29 which is one selected from the group consisting of a Leuconostoc species, a Lactobacil¬ lus species and a Pediococcus species. 34. A strain according to claim 33 which is a strain of Leuconostoc oenos. 35. A strain according to claim 34 wherein the strain of Leuconostoc oenos is selected from the group consisting of DSM 7008, DSM 7009, DSM 7010, DSM 7011, DSM 7012, DSM 7013, DSM 7014 and DSM 7015. 36. A concentrate of a selected strain of a malolactically active bacterium as defined in claim 29. 37. A concentrate according to claim 36 which is a preserved concentrate. 38. A concentrate according to claim to 37 which is a frozen concentrate. 39. A concentrate according to claim 37 which is a freeze- dried concentrate. 40. A concentrate according to claim 36 which is a concen¬ trate having a content of colony forming units being in range of 10 9 to 10 12 per g. 41. A concentrate according to claim 40 which is a concen¬ trate having a content of colony forming units being in the range of lO 11 to 10 12 per g. 42. A concentrate according to claim 36 which is a concen- trate, the direct introduction of which into a wine contain¬ ing at least 4 g of malic acid per L, at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain¬ ing at the most 0.5 g malic acid per L in less than 15 days. 43. A concentrate according to claim 42 which is a concen¬ trate, the direct introduction of which into a wine contain¬ ing at least 4 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain¬ ing at the most 0.5 g malic acid per L in less than 10 days. 44. A concentrate according to claim 43 which is a concen¬ trate, the direct introduction of which into a wine contain¬ ing at least 4 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain¬ ing at the most 0.5 g malic acid per L in less than 8 days. 45. A concentrate according to claim 36 which is a concen¬ trate, the direct introduction of which into a wine contain- ing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain¬ ing at the most 0.5 g malic acid per L in less than 15 days. 46. A concentrate according to claim 45 which is a concen- trate, the direct introduction of which into a wine contain¬ ing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain¬ ing at the most 0.5 g malic acid per L in less than 10 days. 47. A concentrate according to claim 46 which is a concen¬ trate, the direct introduction of which into a wine contain¬ ing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine contain- ing at the most 0.5 g malic acid per L in less than 8 days. 48. A malolactic starter culture composition comprising a concentrate of a selected malolactically active bacterial strain, as defined in claim 36 and at least one further ingredient selected from cryoprotectants, bacterial nutrients and bulking agents. 49. A composition according to claim 48 which is preserved. 50. A composition according to claim 49 which is a frozen composition. 51. A composition according to claim 49 which is a freeze- dried composition. 52. A composition according to claim 48 which is a composi¬ tion having a content of colony forming units being in range of 10 9 to 10 12 per g. 53. A composition according to claim 52 which is a composi¬ tion having a content of colony forming units being in the range of 10 11 to 10 12 per g. 54. A composition according to claim 48 which is a composi- tion, the direct introduction of which into a wine containing at least 4 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 15 days. 55. A composition according to claim 54 which is a composi¬ tion, the direct introduction of which into a wine containing at least 4 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 10 days. 56. A composition according to claim 55 which is a composi¬ tion, the direct introduction of which into a wine containing at least 4 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 8 days. 57. A composition according to claim 48 which is a composi¬ tion, the direct introduction of which into a wine containing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per L of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 15 days. 58. A composition according to claim 57 which is a composi¬ tion, the direct introduction of which into a wine containing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 10 days. 59. A composition according to claim 58 which is a composi- tion, the direct introduction of which into a wine containing at least 5.5 g of malic acid per L at a concentration of CFUs which is in the range of 5 x 10 6 to 5 x 10 7 per mL of the wine, results in a malolactically fermented wine containing at the most 0.5 g malic acid per L within a period of time which is at the most 8 days. 60. A composition according to claim 48 comprising a multi¬ plicity of selected malolactically active bacteria. 61. A composition according to claim 48 wherein the cryo- protectant is gelatine.

Inventors: NIELSEN JAN CLAIR, PRAHL CLAUS, NIELSEN, JAN, CLAIR, PRAHL, CLAUS
Applicants: HANSENS LAB, NIELSEN JAN CLAIR, PRAHL CLAUS, CHR. HANSEN'S LABORATORIUM DANMARK A/S
Application year: 1993
Main classification: C12G1
IPC codes: C12G1, C12H1, C12P7